Fig. 1: Ponatinib dose intensity and change in dose over time. | Leukemia

Fig. 1: Ponatinib dose intensity and change in dose over time.

From: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Fig. 1

A Line graph depicting median dose intensity over time. B Bar graph depicting change in dose over time with only the last dose selected at ≥2 months in (left) the PACE CP-CML cohort and in (right) the OPTIC 45-mg→15-mg cohort. aPACE: Includes 3 patients with CP-CML who did not have a T315I mutation at study entry and were not resistant to dasatinib or nilotinib. CP-CML chronic-phase chronic myeloid leukemia.

Back to article page